Fingerprint
Dive into the research topics of 'Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically